Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK/PD of GLPG3121 in Healthy Male Subjects
NCT03899909Phase 1Completed
- Sponsor
- Galapagos NV
- Start
- Mar 2019
- Primary completion
- Jun 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of GLPG3121 in Inflammatory Disorders (4 arms), sponsored by Galapagos NV. Primary endpoint: Treatment Emergent Adverse Events at 6 months. Started Mar 2019; status: completed.
02
Drugs
GLPG3121
03
Conditions
Inflammatory Disorders
Beyond the preview
Go deeper on NCT03899909.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03899909.